Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
44
MDCX Quote, Financials, Valuation and Earnings
Last price:
$2.11
Seasonality move
:
-37.34%
Day range:
$2.01 - $2.25
52-week range:
$1.68 - $8.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
14.53x
Volume:
406.1K
Avg. volume:
315.1K
1-year change:
-22.86%
Market cap:
$53.4M
Revenue:
--
EPS (TTM):
-$2.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDCX
Medicus Pharma Ltd.
|
-- | -$0.38 | -- | -157.99% | $22.03 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $10.33 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $6.00 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -15.25% | $5.49 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.16 | -- | -43.57% | $55.19 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDCX
Medicus Pharma Ltd.
|
$2.16 | $22.03 | $53.4M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.53 | $16.67 | $2B | 27.68x | $0.00 | 0% | 8.24x |
|
EDSA
Edesa Biotech, Inc.
|
$1.79 | $10.33 | $12.6M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$1.13 | $6.00 | $25.1M | -- | $0.00 | 0% | 28.83x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.98 | $5.49 | $103.7M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$43.52 | $55.19 | $3.4B | -- | $0.00 | 0% | 457.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDCX
Medicus Pharma Ltd.
|
114.82% | -1.403 | 14.49% | 0.81x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 18.80x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDCX
Medicus Pharma Ltd.
|
-- | -$6.7M | -623.93% | -1407.29% | -- | -$6.8M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.8K | -$1.9M | -80.33% | -80.46% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
Medicus Pharma Ltd. vs. Competitors
-
Which has Higher Returns MDCX or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Medicus Pharma Ltd.'s net margin of 42.95%. Medicus Pharma Ltd.'s return on equity of -1407.29% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital MDCXMedicus Pharma Ltd.-- -$1.12 $6.2M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About MDCX or AUPH?
Medicus Pharma Ltd. has a consensus price target of $22.03, signalling upside risk potential of 920.02%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 7.32%. Given that Medicus Pharma Ltd. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Medicus Pharma Ltd. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDCXMedicus Pharma Ltd.2 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is MDCX or AUPH More Risky?
Medicus Pharma Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock MDCX or AUPH?
Medicus Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicus Pharma Ltd. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDCX or AUPH?
Medicus Pharma Ltd. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Medicus Pharma Ltd.'s net income of -$16M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Medicus Pharma Ltd.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicus Pharma Ltd. is -- versus 8.24x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDCXMedicus Pharma Ltd.-- -- -- -$16M AUPHAurinia Pharmaceuticals, Inc.8.24x 27.68x $73.5M $31.6M
-
Which has Higher Returns MDCX or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to Medicus Pharma Ltd.'s net margin of --. Medicus Pharma Ltd.'s return on equity of -1407.29% beat Edesa Biotech, Inc.'s return on equity of -80.46%.
Company Gross Margin Earnings Per Share Invested Capital MDCXMedicus Pharma Ltd.-- -$1.12 $6.2M EDSAEdesa Biotech, Inc.-- -$0.25 $14.1M -
What do Analysts Say About MDCX or EDSA?
Medicus Pharma Ltd. has a consensus price target of $22.03, signalling upside risk potential of 920.02%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 514.53%. Given that Medicus Pharma Ltd. has higher upside potential than Edesa Biotech, Inc., analysts believe Medicus Pharma Ltd. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDCXMedicus Pharma Ltd.2 0 0 EDSAEdesa Biotech, Inc.1 0 0 -
Is MDCX or EDSA More Risky?
Medicus Pharma Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock MDCX or EDSA?
Medicus Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicus Pharma Ltd. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDCX or EDSA?
Medicus Pharma Ltd. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Medicus Pharma Ltd.'s net income of -$16M is lower than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, Medicus Pharma Ltd.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicus Pharma Ltd. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDCXMedicus Pharma Ltd.-- -- -- -$16M EDSAEdesa Biotech, Inc.31.22x -- -- -$1.7M
-
Which has Higher Returns MDCX or LEXX?
Lexaria Bioscience Corp. has a net margin of -- compared to Medicus Pharma Ltd.'s net margin of -2178.51%. Medicus Pharma Ltd.'s return on equity of -1407.29% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital MDCXMedicus Pharma Ltd.-- -$1.12 $6.2M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About MDCX or LEXX?
Medicus Pharma Ltd. has a consensus price target of $22.03, signalling upside risk potential of 920.02%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 371.98%. Given that Medicus Pharma Ltd. has higher upside potential than Lexaria Bioscience Corp., analysts believe Medicus Pharma Ltd. is more attractive than Lexaria Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings MDCXMedicus Pharma Ltd.2 0 0 LEXXLexaria Bioscience Corp.0 0 0 -
Is MDCX or LEXX More Risky?
Medicus Pharma Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock MDCX or LEXX?
Medicus Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicus Pharma Ltd. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDCX or LEXX?
Medicus Pharma Ltd. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Medicus Pharma Ltd.'s net income of -$16M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Medicus Pharma Ltd.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicus Pharma Ltd. is -- versus 28.83x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDCXMedicus Pharma Ltd.-- -- -- -$16M LEXXLexaria Bioscience Corp.28.83x -- $174K -$2.7M
-
Which has Higher Returns MDCX or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to Medicus Pharma Ltd.'s net margin of --. Medicus Pharma Ltd.'s return on equity of -1407.29% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital MDCXMedicus Pharma Ltd.-- -$1.12 $6.2M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About MDCX or ONCY?
Medicus Pharma Ltd. has a consensus price target of $22.03, signalling upside risk potential of 920.02%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 461.59%. Given that Medicus Pharma Ltd. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Medicus Pharma Ltd. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDCXMedicus Pharma Ltd.2 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is MDCX or ONCY More Risky?
Medicus Pharma Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock MDCX or ONCY?
Medicus Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicus Pharma Ltd. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDCX or ONCY?
Medicus Pharma Ltd. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Medicus Pharma Ltd.'s net income of -$16M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Medicus Pharma Ltd.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicus Pharma Ltd. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDCXMedicus Pharma Ltd.-- -- -- -$16M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns MDCX or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Medicus Pharma Ltd.'s net margin of -867.29%. Medicus Pharma Ltd.'s return on equity of -1407.29% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital MDCXMedicus Pharma Ltd.-- -$1.12 $6.2M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About MDCX or XENE?
Medicus Pharma Ltd. has a consensus price target of $22.03, signalling upside risk potential of 920.02%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.19 which suggests that it could grow by 26.82%. Given that Medicus Pharma Ltd. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Medicus Pharma Ltd. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDCXMedicus Pharma Ltd.2 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is MDCX or XENE More Risky?
Medicus Pharma Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.
-
Which is a Better Dividend Stock MDCX or XENE?
Medicus Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicus Pharma Ltd. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDCX or XENE?
Medicus Pharma Ltd. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Medicus Pharma Ltd.'s net income of -$16M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Medicus Pharma Ltd.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicus Pharma Ltd. is -- versus 457.36x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDCXMedicus Pharma Ltd.-- -- -- -$16M XENEXenon Pharmaceuticals, Inc.457.36x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
Buy
54
GDXU alert for Dec 10
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 4.83% over the past day.
